Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. (NASDAQ: SANA) is a biotechnology company focused on creating and delivering engineered cells as medicines, and its news flow reflects this emphasis on cell and gene-based therapies. Company press releases and updates describe progress across its hypoimmune platform for allogeneic cell therapies and its fusogen platform for in vivo delivery of genetic payloads.
Investors following SANA news can read about clinical and preclinical milestones in type 1 diabetes, B-cell cancers, and B-cell–mediated autoimmune diseases. Sana has reported investigator-sponsored clinical data for UP421, a primary human pancreatic islet cell therapy engineered with hypoimmune technology, including results showing survival and function of transplanted beta cells without immunosuppression. News items also cover development of SC451, an O-negative, HIP-modified, iPSC-derived pancreatic islet cell therapy, and in vivo CAR T candidates such as SG299 and SG293 built on the fusogen platform.
In addition to scientific and clinical updates, Sana’s news includes quarterly financial results, portfolio prioritization decisions, and capital-raising activities through public offerings and at-the-market equity programs. The company also issues announcements about participation in healthcare and investor conferences, where management provides business overviews and program updates.
This news page aggregates these disclosures so readers can monitor developments in Sana’s engineered cell programs, regulatory interactions, scientific publications, and financing events associated with the SANA stock. For investors and observers of the biotechnology sector, the SANA news stream offers insight into how the company is advancing its platforms and concentrating resources on type 1 diabetes and in vivo CAR T approaches.
Sana Biotechnology (NASDAQ: SANA) announced plans to present data during four poster presentations at the 63rd American Society of Hematology Annual Meeting, taking place from December 11 to December 14, 2021. This event will highlight advancements in Sana's engineered cell therapies, specifically focusing on in vivo CAR T and ex vivo allogeneic CAR T cell programs. CEO Steve Harr expressed excitement over these scientific developments, emphasizing the company’s goal to file its first IND application as early as next year. The abstracts are available online, with full presentations scheduled throughout the event.
Tessera Therapeutics has announced a collaboration with the Cystic Fibrosis Foundation to utilize its Gene Writing technology for developing treatments for cystic fibrosis. This innovative technology aims to correct genetic mutations causing the disease, which affects around 70,000 people worldwide. The partnership seeks to advance Gene Writers capable of making specific genetic corrections and introducing a functional CFTR gene, targeting a major mutation responsible for 70% of cases. This collaboration may pave the way for groundbreaking therapies in cystic fibrosis treatment.
Sana Biotechnology, Inc. (NASDAQ: SANA) announced a non-exclusive licensing agreement with Beam Therapeutics (NASDAQ: BEAM) for the use of Beam's CRISPR Cas12b nuclease system in Sana's ex vivo engineered cell therapy programs. This agreement allows Sana to utilize the Cas12b system in developing allogeneic T cell and stem cell-derived therapies, with a focus on gene editing for its hypoimmune platform. Sana will make an upfront payment of $50 million to Beam, along with potential milestone and royalty payments based on sales of resulting products.
Sana Biotechnology (NASDAQ: SANA) will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 2:00 p.m. PT. The presentation, hosted by CEO Steve Harr, will offer insights into the company's business and updates on its innovative approaches in engineered cell therapies. Interested parties can access the live webcast on Sana's Investor Relations page, with a replay available for 30 days post-conference. Sana aims to revolutionize medicine through gene repair and cell replacement, employing a dynamic team of over 320 professionals across Seattle, Cambridge, and South San Francisco.
MaxCyte has signed a clinical and commercial license agreement with Sana Biotechnology, granting Sana the rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte will receive licensing fees and milestone payments. Doug Doerfler, MaxCyte's CEO, expressed enthusiasm for supporting Sana's cell therapy programs, highlighting the potential of Sana's hypoimmune cell platform. This collaboration aims to enhance the development of innovative cell-based treatments, reinforcing MaxCyte's position in the biopharmaceutical sector.
Sana Biotechnology reported its Q2 2021 results, highlighting a cash position of $930.8 million, significantly up from $412.0 million in Q4 2020. The company presented data showing immune evasion in transplanted hypoimmune cells in primates without immunosuppression, advancing its engineered cell therapies. A long-term lease was signed for a 163,000 square foot manufacturing facility in Fremont, California, to support clinical and commercial products. The net income for Q2 was $18.7 million, representing $0.10 per share, while the net loss for the first half was $161.9 million, or $1.08 per share.
Sana Biotechnology (NASDAQ: SANA) has announced plans to develop a new 163,000 square foot manufacturing facility in Fremont, California. This facility aims to support late-stage clinical development and early commercial product candidates. CEO Steve Harr emphasized that this facility is crucial for addressing manufacturing challenges in cell and gene therapies. The new site will enhance Sana's capabilities in producing allogeneic T cells, viral vectors, and pluripotent stem cells while maintaining proximity to existing technical expertise and a strong biotech workforce.
Sana Biotechnology, Inc. (NASDAQ: SANA) will present significant data at the International Society for Stem Cell Research 2021 Virtual Annual Meeting from June 21-26. Chuck Murry, M.D., will discuss 'Genome Editing to Eliminate Engraftment Arrhythmia' on June 21, while Sonja Schrepfer, M.D., will present on immune protection of transplanted stem cells on June 26. Both presentations will be available for on-demand viewing through July 31. Sana aims to advance engineered cells as medicines for various diseases, supported by a dedicated team across multiple locations.
Sana Biotechnology (NASDAQ: SANA) announced it will webcast its presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 12:00 p.m. PT. CEO Steve Harr will provide a business overview and update. The webcast can be accessed on Sana's Investor Relations page, with a replay available for 30 days post-conference. Sana Biotechnology focuses on engineered cells as therapies, aiming to transform disease treatment.
Sana Biotechnology, Inc. (NASDAQ: SANA) reported first-quarter 2021 results, highlighting a cash position of $981.9 million, a significant increase from $412.0 million at year-end 2020. The company presented proof of concept data at the AACR 2021 conference, showcasing its in vivo and ex vivo CAR T cell therapy platforms. However, it incurred a net loss of $180.6 million for the quarter, up from $32.9 million in Q1 2020. R&D expenses soared to $168.9 million, driven by increased headcount and preclinical studies.
FAQ
What is the current stock price of Sana Biotechnology (SANA)?
What is the market cap of Sana Biotechnology (SANA)?
